PPP1R9B

Across TCGA pan-cancer cohorts, PPP1R9B mass-spec protein differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of PPP1R9B’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where PPP1R9B mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types PPP1R9B is over-expressed in tumor, although a few such as LUAD and LSCC show the opposite, repressed pattern.

CCRCC, LUAD, and LSCC are the cancer types where PPP1R9B tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in PPP1R9B mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Male	All	+0.497	<.001	12	view →
LUAD	Female	II,III,IV	−0.264	<.001	9	view →
LSCC	Male	III,IV	−0.328	<.001	8	view →
HNSC	Male	II,III,IV	+0.224	<.001	8	view →
COAD	All	II,III,IV	+0.111	<.001	8	view →
OV	All	All	−0.287	.037	2	view →
PDAC	All	IV	−0.567	.049	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

PPP1R9B–CCRCC

Open the CCRCC breakdown →